Trial Profile
A phase I trial assessing lapatinib + cisplatin + hyperthermia in patients with recurrent cervical cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 24 Nov 2015 New trial record